Last Updated: September 24, 2026

Details for Patent: 10,449,173

Name: Drug Patent Intelligence for US Patent 10449173
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,449,173 protect, and when does it expire?

Patent 10,449,173 protects GELNIQUE and is included in one NDA.

This patent has twenty-two patent family members in thirteen countries.

Summary for Patent: 10,449,173

Title:	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Abstract:	The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
Inventor(s):	Scott Gochnour, Venkatesh Subramanyan, Michael W. Kimball
Assignee:	Actavis Laboratories UT Inc , Allergan Sales LLC
Application Number:	US14/988,203
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,449,173

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009		DISCN	Yes	No	10,449,173	⤷ Start Trial	Y			TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,449,173

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010246103	⤷ Start Trial
Brazil	PI1015542	⤷ Start Trial
Canada	2760867	⤷ Start Trial
Canada	2821174	⤷ Start Trial
China	102421411	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.